Breast Cancer

The largest study to date comparing outcomes of radiation therapy and postmastectomy breast reconstruction found higher rates of complication and failure in women who received radiation therapy and had implant reconstruction versus autologous reconstruction.
Endocrine therapy is known to reduce breast cancer risk by 30% when used as primary prevention in women at risk for the disease, and the reduction lasts for at least 20 years.
Breast cancer rates are increasing worldwide, paralleling increases in type 2 diabetes, obesity, and metabolic syndrome (MetS).
Breast density, which can affect the visualization of mammography, is one of the strongest and most consistent risk factors for breast cancer.
Occupational factors such as shift work disrupt circadian rhythm and can increase breast cancer risk, and the International Agency for Research on Cancer has classified shift work as a possible carcinogen.
Several studies have shown that Ki67 is an independent prognostic factor in patients with breast cancer, and Ki67 is included in the Oncotype DX test that estimates the likelihood of breast cancer recurrence and the need for chemotherapy.
Duloxetine relieved musculoskeletal symptoms in a significant proportion of postmenopausal patients with breast cancer receiving treatment with aromatase inhibitors (AIs) in a randomized trial (SWOG S1202).
Measuring the Ki67 protein, along with traditional risk factors such as tumor size and molecular characteristics, may make it possible to avoid sentinel node biopsy in women aged >50 years with breast cancer.

Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene–based assay was used to guide treatment decision­-making, according to new data presented at the 2016 American Association for Cancer Research meeting.

Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene–based assay was used to guide treatment decision­-making, according to new data presented at the 2016 American Association for Cancer Research meeting.

Page 1 of 12
Results 1 - 10 of 111